Biotheranostics Announces Inclusion of Breast Cancer Index in the National Comprehensive Cancer Network (NCCN) Breast Cancer Guidelines for Prediction of Benefit from Extended Endocrine Therapy

Products

Biotheranostics Mission

Individualizing cancer care and improving patients’ lives by translating scientific discovery into novel molecular tests.

In ER+ early-stage breast cancer

The only robust, validated tool to help with clinical decision-making for extended endocrine treatment.

Actionable genomic information for accurate diagnosis and treatment for metastatic patients with diagnostic ambiguity